MicroRNA Market Report

MicroRNA Market Analysis, Market Size, Application Analysis, Regional Outlook, Competitive Strategies And Forecasts, 2016 To 2024

Format: PDF  |  Report ID: GVR4567

The global microRNA market worth is expected to exceed USD 1.7 billion by 2024 and is estimated to grow at a CAGR of over 18% from 2016 to 2024. It plays a significant role in plants and animals by targeting specific mRNAs for degradation or translation repression.

Growing number of biotech and pharmaceutical companies involved in various research advancements such as molecular diagnostics and therapeutics is expected to drive the market growth over the forecast period. These factors offer growth and ample opportunities to different segments including virology, cardiovascular, endocrinology, genetic disease, and plant science.

One of the major factors contributing to industry growth is the provision of large scale funding by private and public sectors. Government investment and increasing technological developments are further anticipated to drive market growth. Factors mentioned above are expected to urge pharmaceutical and biotech companies to enhance R&D investments in different disease classes.

Increasing occurrence of illness, such as cardiovascular and cancer globally, is expected to drive the market for the foreseeable future. According to WHO, about 13 million cancer cases were reported in 2008 and the incidents reached 14 million in 2012 and is further estimated to grow at a significant rate.

Recent innovations include diverse applications of microRNA technology can also be attributed to the major factors driving the market growth. This technique is used as a biomarker for cancer treatment and diagnosis. Increasing investments in R&D initiatives in developing new diagnostic tests and therapeutics is also expected to fuel the product demand over the next eight years.

Increased target selectivity and specificity of RNAi therapeutics, along with adoption of virtual drug development models enables companies to minimize costs associated with research and production. One of the key strategy adopted by the industry participants includes shifting from platform technologies to developing application specific products.

Developing drugs or biologics through virtual drug development platform offers significant advantages over traditional models. This provides ample opportunities for minimizing risks and overhead costs associated with conventional technologies.miRNAs play a major role in various biological processes including the developmental timing, cell proliferation, apoptosis, stem cell maintenance, differentiation, signaling pathways, and pathogenesis, such as carcinogenesis.

Stringent regulations and high investment cost are expected to be the major restraints for the microRNA market. High costs associated with equipment used in detecting miRNA along with extensive and time-consuming testing methods, subsequently contributes in increasing overall research value. High failure rate coupled with the lack of skilled professionals with superior industry experience may hamper market growth.

However, increasing collaborations and mergers biotechnology firms with government research agencies is expected to influence positively industry expansion. New research and patents related to nanomaterial conjugation with microRNA molecules are anticipated to create immense potential for future developments particularly in the field of nanotherapeutics and nanomedicine.

Global microRNA market has been segmented based on various therapeutics including research tools, diagnostic technologies, and reagents. Research tool was the leading therapeutic part in 2014. Diagnostic technologies are anticipated witnessing the fastest growth in next nine years owing to increasing demand for cancer treatment and clinical experiments.

By technology, the global market has been segmented into enabled and enabling technologies. Enabling technologies segment comprises purification, labeling, linear amplification, microarrays, art-PCR, and inhibition. Enabled technologies can be further bifurcated into interference (RNAi) and antisense technology.

Enabled Technologies segment is projected to account for the largest share in the industry owing to their significant use in therapeutics. RNAi technology is expected to dominate the therapeutic segment due to increasing investment in drug development.

RNA therapeutics have various applications that comprise chronic conditions including kidney diseases, cardiovascular, oncology, metabolic disorders, and cardiovascular. Shifting preference towards infectious and oncology diseases in the industry pipeline research may be attributed to their high occurrence and failure rate of existing treatment processes.

By end-use, the market has been segmented into medical diagnostics, research, and therapeutics. Research and medical diagnostics sectors are expected to enhance the effectiveness of technology and therapies associated with the RNA drugs. Therapeutics is projected to witness significant growth owing to increasing prevalence of various diseases and increased microRNA use in cancer and tumor therapies owing to their biocompatibility nature.

North America and Europe are foreseen to dominate the global microRNA demand due to the presence of advanced life science research infrastructures and R&D organizations in these regions. The U.S. represents the largest market followed by Canada in North America. France, Germany, Italy, U.K, and Spain are anticipated to hold a significant share in the European industry.

Asia-Pacific is projected to witness significant growth rate over the forecast period owing to increased investment by major companies in the region. Also, less stringent regulations are expected to steer the market growth in the region. India and China are projected to be the fastest-growing markets in the area.

Key players operating in the global microRNA industry include Alnylam Pharmaceuticals Inc., Affymetrix, Santaris Pharma, AstraZeneca Pharmaceuticals LP, Exiqon, Biogen Idec Inc. Other industry participants include Pfizer Inc., Eli Lilly and Co., CBC Biomarker Center GmbH, GlaxoSmithKline, F. Hoffman-La Roche, Merck & Co, and Novartis AG.

Although the developmental stage, recent innovations in R&D has enhanced investments in medical sector for conducting clinical tests and developing drugs for various diseases. Ongoing investments in R&D coupled with favorable government initiatives such as collaboration with research organizations is expected to drive market growth over the next eight years.

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA